Extended Data Figure 6 Binding of GLP-1 and exendin-4 (9-39) to representative constructs
Each individuals health needs are unique, and personalizing any supplementation plan can help optimize results 3
These pens are all-or-nothing devices
[Drug Metabolism and Disposition, 2014, vol
Effectiveness Injectable tirzepatide, studied in the SURMOUNT clinical trial program involving thousands of participants, produced average weight loss of 15 to 22.5% of body weight over 72 weeks at the highest doses
Compounded GLP-1 products are marketed using semaglutide or tirzepatide formulations, but they are distinct from FDA-approved finished brand-name drugs like Ozempic, Wegovy, Zepbound, or Mounjaro